Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Average Recommendation of “Moderate Buy” from Analysts
Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) has earned an average rating of “Moderate Buy” from the eighteen analysts that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold recommendation, fifteen have given a buy recommendation and one has given a strong buy recommendation to the company. The […]
Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) has earned an average rating of “Moderate Buy” from the eighteen analysts that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold recommendation, fifteen have given a buy recommendation and one has given a strong buy recommendation to the company. The […]
